25 September 2009

Double chemo dose helps patients

Adults with a common form of leukaemia had a better chance of remission if they got a double dose of a long-used cancer drug, two new studies found.


Adults with a common form of leukaemia had a better chance of remission if they got a double dose of a long-used cancer drug, two new studies found.

Doctors said the findings should change the standard of care for younger adults with acute myeloid leukaemia, but work remains to find better treatment for the elderly, who are more likely to develop the disease.

Acute myeloid leukaemia is a cancer of the blood and bone marrow.

Most common type in adults
It's the most common type of acute leukaemia in adults. About 12,810 new cases will be diagnosed in the United States this year, according to the Leukaemia & Lymphoma Society.

Patients typically receive two chemotherapy drugs to slow or stop the growth of cancer cells in the body. Two studies published in Thursday's New England Journal of Medicine looked at how patients fared if the dose of one of the chemo drugs, daunorubicin, was doubled.

One study led by researchers at the Moffitt Cancer Center and Research Institute in Florida gave 657 leukemia patients ages 17 to 60 either the standard chemo dose or double the amount and followed them for about two years.

Higher does = complete remission
Complete remission occurred in 71% of those who took the higher dose, compared with 57% in the regular dose group. Overall survival was also higher in those who had more chemo: 24 months versus 16 months.

The other study led by Erasmus University Medical Center in the Netherlands looked at an older population - ages 60 to 83 and followed them for three years. Of the 813 volunteers newly diagnosed with AML, 64% in the double-dose group had complete remission compared with 54% in the standard dose group.

Overall, there was no difference in survival between the two groups, except those under 65 who got the double dose did better.

Higher dose for younger patients
In an accompanying editorial, Drs. Herve Dombret and Claude Gardin of Hospital Saint-Louis in Paris wrote that the results warrant giving younger leukaemia patients a higher chemo dose. Since many elderly patients will not benefit from more chemo, doctors need to find new ways to help this age group, they said.

The American study was funded by the National Cancer Institute and Department of Health and Human Services. One of the authors received support from Wyeth Pharmaceuticals and Immunex, which make chemo drugs. The European study was supported by the Dutch Cancer Society Queen Wilhelmina Foundation.- (Sapa-AP , September 2009)

Read more:
Leukaemia cells hide in fat tissue
Young cancer patients live longer


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules